Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$AMMJ .25 was the breakout level!! Now clear skys imo!
$AMMJ going hard here!!
Yes, the million dollar question everyone wants to know is the bull market we've enjoyed(some of us less so) is it over? I believe the evidence suggests that it is and this would then be the first rally in a new bear market. Death crosses are not something to take lightly, and the way we have been topping out and breaking long dated trend lines is not something for the bulls to get excited about long term. Just look at $SSEC the Chinese market, its ugly. I believe with time it will probably see 2000-ish again and I could see 1600 on the S&P. But as of right now it may bounce a lil bit say 3400 around its 50 day?
Book it as happening just look at the chart of IBB again.
Yes, but until we are back below the 50 day the bulls are in full control and whats more is that 200 day is going to act as a magnet for the markets to be pulled to.
Yes, a doji at resistance indicating that it wasn't ready on Friday. Healthy consolation and it shall try again and more than likely succeed this week in crude's attempt at taking the 200 on the daily. We shall see!! My money is on continued crude strength. Short term indicators can stay over-bought or over-sold for a long time as I'm sure you are aware.
Yes QQQ, IBB, and IWM are all under-performing the SPY really. That only hints of more fuel for more strength to come IMO. Check out last years October move. Lasted till years end. I'm thinking this move will be very similar. I'm looking for the 200 to be taken out and to test the 2100 area. We have already conquered the 50 here folks. Wait for the market to tell you very clearly to short it. Now is not the time IMO. One thing is for sure it will come again.
I could see IBB going up to touch its 50 SMA again up around 340 and its hard to imagine that being bad news for the SPY no?
Of course it should go without saying that I never root for bloodshed.
As long as it causes oil to rise. I'm cool with it.
Great trade of NFLX there Roy. I followed you in on a paper trade with it but chickened out with putting real $$$ on the line. I've been following you & a few others in the shadows and I can tell you really know what your doing & I appreciate you posting your trades for all to see. I'll look dip my toes into option trading myself within the next couple weeks.
What's your call for tomorrow now? A rise up to touch the middle BB/ the 20sma?
Yup, I agree 100%... Tomorrow we start the ascent towards the .40's again
Too much volume, meaning $$$ in a lot higher for this to just drop into the upper teens.
For what its worth, I hope and believe that you are mistaken.
Bounce is a coming!! Added big @ .27
Closing strong! My gut tells me we see .50+ tomorrow!
Yup, I also banked good coin on CYTX & I'm in complete agreement here we are gonna explode to the 200SMA real soon here. Get your tickets before the train leaves without you.
NSPH the next CYTX
NSPH the next CYTX
Acasti (ACST) Receives Full Data for Phase II TRIFECTA Trial
Well Positioned to Discuss Next Steps With FDA
Closing above the 50 SMA would be a great sign here.
Hope it does. I'll trade it again ;) Rise,wash,repeat.
out @ .001 from .0007... Trade em don't love em
Added a million like I said I would. For me that was all profit from above. Hope it moves again now. Lets pump it up lol
ACST RUNNING HERE WITH VOL
Just a common sense observation here. If you look at a chart with volume of BYSD you will see that on February 18th there was 256,274,608 shares traded between .003-.007 and then in just a few trading days later the price is trading in the mid .002's. Now I ask doesn't it make sense that those who front loaded this thing in the .000's are gonna take some profit in the mid .002's?
Some lessons are expensive to learn but if you walk away from the experience learning something then it was worth the cost.
Yes, I most likely will trade this again now that it has come in. Just a word of wisdom to the board. Don't fall in love with these sub penny stocks or else they will eat your breakfast. I'm worried the whole story is complete B.S. there is no buyout agreement and some self proclaimed CEO is lining their pockets with endless diluted shares. I've seen it time and time again and the SEC hardly ever takes action. Then again I've been in companies that the SEC did eventually become privy to scams and suspended the stock, then only to move it to the grey sheets. Ok now you pumpers and people now stuck at higher prices can now crucify me. Go ahead! All my opinion of course.
If it falls to .007 I may take a stab at another million.
What goes up must come down. Thankful I got out in the .002's
Gonna see new highs after lunch!
CYTX GOING TO A $1 TODAY IMO!!!
Great Chart~Great Story! Glad to be with you guys in here. We're gonna make a run at that 200 day SMA @ 1.20 and beyond mark this post!!!
Cytori Receives Positive European Opinion on Orphan Drug Status
1 hours 51 minutes ago - DJNF
SAN DIEGO--(BUSINESS WIRE)--February 24, 2015--
Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that the European Medicines Agency's Committee for Orphan Medicinal Products (COMP) issued a positive opinion toward Cytori's application for an orphan drug designation for the new Scleroderma therapeutic ECCS-50, which contains adipose tissue-derived stromal vascular fraction cells derived from Cytori's proprietary Celution(R) System.
Cytori has also recently received FDA approval to study the same therapeutic, ECCS-50, in an 80 patient Phase 3 pivotal study for Scleroderma associated hand dysfunction. This trial is currently planned to begin enrolling this year in approximately 12 U.S. sites.
"The COMP's supportive opinion is first and foremost a key step toward receiving orphan designation in the European Union for Cytori Cell Therapy(R) in Scleroderma associated hand dysfunction," said Dr. Marc Hedrick, President and CEO of Cytori Therapeutics, "In the bigger picture, this opinion is a validating event for our broader strategy to achieve disease-specific claims and reimbursement in nearer term indications, such as those for orphan indications."
"Orphan designation in Europe comes with significant benefits," said Ken Kleinhenz, Cytori Vice President of Global Regulatory and Quality Affairs. "Companies who obtain orphan designation from the European Commission benefit from a number of incentives including: protocol assistance, significant fee reductions, access to the centralized procedures, and market exclusivity of 10 years once the medicine is on the market."
Orphan medicines are eligible to be assessed through the centralized procedure that allows companies to make a single application to the European Medicines Agency that would result in a single opinion and a single decision from the European Commission that would be valid in all EU Member States. Conditional approval is also available to orphan medicines through the centralized process. Orphan medicines benefit from ten years of protection from market competition with similar medicines with similar indications once they are approved.(1)
"We have been extremely encouraged by the positive results from our open label clinical trial evaluating Cytori Cell Therapy (autologous adipose derived stromal vascular fraction) in patients with impaired hand function due to Scleroderma. The orphan status should help accelerate our ability to ultimately provide Cytori Cell Therapy (autologous adipose derived stromal vascular fraction) to our patients who are truly in need of additional effective therapies," said Prof. Brigitte Granel from the North Hospital, Assistance Publique Hopitaux de Marseilles and first author of the publication describing the results of the SCLERADEC--I trial.(2)
About Cytori Therapeutics, Inc.
Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy(TM) acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy(TM) may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori's proprietary technologies and products. For more information: visit www.cytori.com.
Cautionary Statement Regarding Forward-Looking Statements
This communication includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, but not limited to, those regarding our ability to achieve orphan designation for Cytori Cell therapy, and the impact of such designation in accelerating the availability of Cytori Cell Therapy to treat patients in Europe, are forward looking statements. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks include clinical and regulatory uncertainties, the challenges inherent in convincing physicians and patients to adopt the new technology, dependence on third party performance, performance and acceptance of our products, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings, including in its most recent annual and quarterly reports. Cytori assumes no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends or circumstances after the date of this communication.
1. Regulation (EC) No 141/2000 on orphan medicinal products (http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en:PDF).
2. Granel B, Dauma A, Jouve E, Harle JR, Nguyen PS, Chabannon C, Colavolpe N, Reyneir JC, Truillet R, Mallet S, Baiade A, Casanova D, Giraudo L, Arnaud L, Veran J, Sabatier F, Magalon G. Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: an open-label phase I trial. Ann Rheum Dis 2014; doe:10.1136/annrheumdis-2014-205681
CONTACT: Cytori Therapeutics, Inc.
Shawn Richardson, 858-875-5279
ir@cytori.com
SOURCE: Cytori Therapeutics, Inc.
Copyright Business Wire 2015
(END) Dow Jones Newswires